BACKGROUND: Short QT syndrome (SQTS) is a primary electrical disease of the heart associated with a high risk of sudden cardiac death. A gain-of-function in I(Kr), due to a mutation in KCNH2, underlies SQT1. OBJECTIVE: This study sought to examine the cellular basis for arrhythmogenesis in an experimental model of SQT1 created using PD-118057, a novel I(Kr) agonist. METHODS: Transmembrane action potentials were simultaneously recorded from epicardial, M, and endocardial regions of arterially perfused canine left ventricular (LV) wedge preparations, together with a pseudo-electrocardiogram. RESULTS: PD-118057 (10 micromol/l) abbreviated the QT interval from 267 +/- 4 to 232 +/- 4 ms and increased transmural dispersion of repolarization (TDR) from 33.7 +/- 2.0 to 49.1 +/- 3.1 ms (P <.001). T-wave amplitude increased from 18.0% +/- 1.4% to 23.1% +/- 1.7% of R-wave amplitude (P =.027). Reversing the direction of activation of the LV wall (epicardial pacing) resulted in an increase in QT interval from 269 +/- 5 to 282 +/- 5 ms and an increase in TDR from 34.1 +/- 2.0 to 57.6 +/- 3.3 ms (P <.001) under baseline conditions. PD-118057 abbreviated the QT interval from 282 +/- 5 to 258 +/- 5 ms and produced a proportional decrease in effective refractory period (ERP). TDR increased from 57.6 +/- 3.3 to 77.6 +/- 4.3 ms (P <.001). Polymorphic ventricular tachycardia (pVT) was induced in 10 of 20 preparations with a single S(2) applied to epicardium. Quinidine (10 micromol/l) increased the ERP and QT interval, did not significantly alter TDR, and prevented induction of pVT in 5 of 5 preparations. CONCLUSION: Our results suggest that a combination of ERP abbreviation and TDR amplification underlie the development of pVT in SQT1 and that quinidine prevents pVT principally by prolonging ERP.
BACKGROUND:Short QT syndrome (SQTS) is a primary electrical disease of the heart associated with a high risk of sudden cardiac death. A gain-of-function in I(Kr), due to a mutation in KCNH2, underlies SQT1. OBJECTIVE: This study sought to examine the cellular basis for arrhythmogenesis in an experimental model of SQT1 created using PD-118057, a novel I(Kr) agonist. METHODS: Transmembrane action potentials were simultaneously recorded from epicardial, M, and endocardial regions of arterially perfused canine left ventricular (LV) wedge preparations, together with a pseudo-electrocardiogram. RESULTS:PD-118057 (10 micromol/l) abbreviated the QT interval from 267 +/- 4 to 232 +/- 4 ms and increased transmural dispersion of repolarization (TDR) from 33.7 +/- 2.0 to 49.1 +/- 3.1 ms (P <.001). T-wave amplitude increased from 18.0% +/- 1.4% to 23.1% +/- 1.7% of R-wave amplitude (P =.027). Reversing the direction of activation of the LV wall (epicardial pacing) resulted in an increase in QT interval from 269 +/- 5 to 282 +/- 5 ms and an increase in TDR from 34.1 +/- 2.0 to 57.6 +/- 3.3 ms (P <.001) under baseline conditions. PD-118057 abbreviated the QT interval from 282 +/- 5 to 258 +/- 5 ms and produced a proportional decrease in effective refractory period (ERP). TDR increased from 57.6 +/- 3.3 to 77.6 +/- 4.3 ms (P <.001). Polymorphic ventricular tachycardia (pVT) was induced in 10 of 20 preparations with a single S(2) applied to epicardium. Quinidine (10 micromol/l) increased the ERP and QT interval, did not significantly alter TDR, and prevented induction of pVT in 5 of 5 preparations. CONCLUSION: Our results suggest that a combination of ERP abbreviation and TDR amplification underlie the development of pVT in SQT1 and that quinidine prevents pVT principally by prolonging ERP.
Authors: Victor A Medina-Ravell; Ramarao S Lankipalli; Gan-Xin Yan; Charles Antzelevitch; Napoleon A Medina-Malpica; Otto A Medina-Malpica; Christopher Droogan; Peter R Kowey Journal: Circulation Date: 2003-02-11 Impact factor: 29.690
Authors: Ramon Brugada; Kui Hong; Robert Dumaine; Jonathan Cordeiro; Fiorenzo Gaita; Martin Borggrefe; Teresa M Menendez; Josep Brugada; Guido D Pollevick; Christian Wolpert; Elena Burashnikov; Kiyotaka Matsuo; Yue Sheng Wu; Alejandra Guerchicoff; Francesca Bianchi; Carla Giustetto; Rainer Schimpf; Pedro Brugada; Charles Antzelevitch Journal: Circulation Date: 2003-12-15 Impact factor: 29.690
Authors: Chloé Bellocq; Antoni C G van Ginneken; Connie R Bezzina; Mariel Alders; Denis Escande; Marcel M A M Mannens; Isabelle Baró; Arthur A M Wilde Journal: Circulation Date: 2004-05-25 Impact factor: 29.690
Authors: Silvia G Priori; Sandeep V Pandit; Ilaria Rivolta; Omer Berenfeld; Elena Ronchetti; Amit Dhamoon; Carlo Napolitano; Justus Anumonwo; Marina Raffaele di Barletta; Smitha Gudapakkam; Giuliano Bosi; Marco Stramba-Badiale; José Jalife Journal: Circ Res Date: 2005-03-10 Impact factor: 17.367
Authors: Brian Cross; Munther Homoud; Mark Link; Caroline Foote; Ann C Garlitski; Jonathan Weinstock; N A Mark Estes Journal: J Interv Card Electrophysiol Date: 2011-04-14 Impact factor: 1.900
Authors: Jiqing Guo; Yen May Cheng; James P Lees-Miller; Laura L Perissinotti; Tom W Claydon; Christina M Hull; Samrat Thouta; Daniel E Roach; Serdar Durdagi; Sergei Y Noskov; Henry J Duff Journal: Biophys J Date: 2015-03-24 Impact factor: 4.033
Authors: José M Di Diego; Serge Sicouri; Rachel C Myles; Francis L Burton; Godfrey L Smith; Charles Antzelevitch Journal: J Mol Cell Cardiol Date: 2012-11-09 Impact factor: 5.000
Authors: Lin Wu; Donglin Guo; Hong Li; James Hackett; Gan-Xin Yan; Zhen Jiao; Charles Antzelevitch; John C Shryock; Luiz Belardinelli Journal: Heart Rhythm Date: 2008-09-06 Impact factor: 6.343